Cannabinoid Ligands with Fluorescent Moieties for Receptor Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing fluorescent ligands for cannabinoid receptors face challenges such as low affinity/specificity, inadequate photophysical properties, extensive non-specific binding, and low signal-to-noise ratio, particularly for agonist-based probes, which hinders effective imaging and therapeutic applications.
Innovation Solution
Development of novel cannabinoid ligands incorporating imaging/diagnostic and therapeutic functional groups like fluorescent moieties, nitroxide spin labels, metal chelates, and biotin moieties with enhanced polarity, which can bind tightly and irreversibly to CB1/CB2 receptors, enabling improved imaging and therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If agonist-based fluorescent probes are used for cannabinoid receptor imaging, then the ligands can bind to CB1/CB2 receptors, but the affinity and specificity are low and non-specific binding is extensive
Solution Approach 1:
The patent modifies the chemical structure of cannabinoid ligands by incorporating fluorescent moieties at specific positions and using heterocyclic substitutions to optimize binding characteristics. This structural parameter changes enable high affinity and specificity for CB1/CB2 receptors while minimizing non-specific binding, directly resolving the contradiction between binding reliability and harmful non-specific interactions.
Solution Approach 2:
The patent creates composite molecular structures by combining cannabinoid core structures with fluorescent groups, heterocyclic moieties, and polar functional groups. This composite approach produces ligands that simultaneously achieve high receptor specificity and reduced non-specific binding, as the multiple functional components work together to enhance target selectivity while maintaining imaging capabilities.
2Ease of manufacture
If fluorescent groups are incorporated into cannabinoid ligands, then imaging capabilities are enabled, but photophysical properties are inadequate and signal-to-noise ratio is low
Solution Approach 1:
The patent strategically places fluorescent moieties at specific positions on the cannabinoid ligand structure rather than uniformly distributing them. This local quality approach ensures that the fluorescent groups are positioned to maximize signal emission while minimizing quenching effects and non-specific binding, thereby improving signal-to-noise ratio without sacrificing imaging capability.
Solution Approach 2:
The patent uses fluorescent groups as optical copies or surrogates for the pharmacophoric elements of cannabinoid ligands. These fluorescent moieties replicate the binding characteristics of the parent compounds while providing detectable optical signals, enabling imaging with high signal-to-noise ratio by optimizing the photophysical properties of the fluorescent copy.
3Reliability
If novel ligands with enhanced polarity are developed, then binding affinity and specificity improve, but the complexity of ligand structure increases
Solution Approach 1:
The patent divides the ligand structure into distinct functional segments: a cannabinoid core structure for receptor binding, heterocyclic moieties for enhanced polarity and specificity, and fluorescent groups for imaging. This segmentation allows each component to be optimized independently for its specific function, achieving high binding affinity and specificity without excessive overall complexity.
Solution Approach 2:
The patent designs ligands where single structural elements serve multiple functions: heterocyclic moieties simultaneously enhance polarity for improved binding specificity and provide sites for fluorescent group attachment. This multi-functionality reduces overall structural complexity while maintaining high binding affinity and specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel ligands provide high affinity and specificity for cannabinoid receptors, enhancing imaging capabilities and therapeutic efficacy for various physiological and pathological conditions, including pain management, neurodegenerative diseases, and inflammatory disorders, while maintaining or increasing bioactivity.
Implementation Method 1
fluorescent groups, nitroxide spin labels, metal chelates, biotin moieties
Implementation Method 2
nitroxide spin labels
Implementation Method 3
metal chelates
Data Source
AI summary
Novel cannabinoid ligands represented by the general formulas I, II, and III and methods for preparation and use within which one or more of a fluorescent ligand, nitroxide spin label, metal chelate, biotin moiety, or group with enhanced polarity may be incorporated. The compounds can bind to and modulate the cannabinoid CB1 and CB2 receptors and thereby considered specific ligands for these receptors. Some of the disclosed compounds that bind to cannabinoid CB1 and CB2 receptors can exhibit tight or irreversible binding characteristics for these receptors. Due to the presence of the imaging/diagnostic and/or therapeutic functional groups including fluorescent groups, nitroxide spin labels, metal chelates, biotin moieties, and groups with enhanced polarity, the disclosed compounds may be useful as imaging/diagnostic tools and/or therapeutic agents.